582 related articles for article (PubMed ID: 23125217)
1. Interleukin-17 induces AP-1 activity and cellular transformation via upregulation of tumor progression locus 2 activity.
Kim G; Khanal P; Lim SC; Yun HJ; Ahn SG; Ki SH; Choi HS
Carcinogenesis; 2013 Feb; 34(2):341-50. PubMed ID: 23125217
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-22 promotes epithelial cell transformation and breast tumorigenesis via MAP3K8 activation.
Kim K; Kim G; Kim JY; Yun HJ; Lim SC; Choi HS
Carcinogenesis; 2014 Jun; 35(6):1352-61. PubMed ID: 24517997
[TBL] [Abstract][Full Text] [Related]
3. Luteolin, a novel natural inhibitor of tumor progression locus 2 serine/threonine kinase, inhibits tumor necrosis factor-alpha-induced cyclooxygenase-2 expression in JB6 mouse epidermis cells.
Kim JE; Son JE; Jang YJ; Lee DE; Kang NJ; Jung SK; Heo YS; Lee KW; Lee HJ
J Pharmacol Exp Ther; 2011 Sep; 338(3):1013-22. PubMed ID: 21705614
[TBL] [Abstract][Full Text] [Related]
4. Tpl-2 kinase downregulates the activity of p53 and enhances signaling pathways leading to activation of activator protein 1 induced by EGF.
Khanal P; Lee KY; Kang KW; Kang BS; Choi HS
Carcinogenesis; 2009 Apr; 30(4):682-9. PubMed ID: 19221002
[TBL] [Abstract][Full Text] [Related]
5. Tpl2 is a key mediator of arsenite-induced signal transduction.
Lee KM; Lee KW; Bode AM; Lee HJ; Dong Z
Cancer Res; 2009 Oct; 69(20):8043-9. PubMed ID: 19808956
[TBL] [Abstract][Full Text] [Related]
6. Dominant-negative c-Jun (TAM67) target genes: HMGA1 is required for tumor promoter-induced transformation.
Dhar A; Hu J; Reeves R; Resar LM; Colburn NH
Oncogene; 2004 May; 23(25):4466-76. PubMed ID: 15064752
[TBL] [Abstract][Full Text] [Related]
7. IL-17R activation of human periodontal ligament fibroblasts induces IL-23 p19 production: Differential involvement of NF-κB versus JNK/AP-1 pathways.
Zhu L; Wu Y; Wei H; Xing X; Zhan N; Xiong H; Peng B
Mol Immunol; 2011 Jan; 48(4):647-56. PubMed ID: 21145111
[TBL] [Abstract][Full Text] [Related]
8. Activation of extracellular signal-regulated kinase and c-Jun-NH(2)-terminal kinase but not p38 mitogen-activated protein kinases is required for RRR-alpha-tocopheryl succinate-induced apoptosis of human breast cancer cells.
Yu W; Liao QY; Hantash FM; Sanders BG; Kline K
Cancer Res; 2001 Sep; 61(17):6569-76. PubMed ID: 11522656
[TBL] [Abstract][Full Text] [Related]
9. Expression of dominant negative Erk2 inhibits AP-1 transactivation and neoplastic transformation.
Watts RG; Huang C; Young MR; Li JJ; Dong Z; Pennie WD; Colburn NH
Oncogene; 1998 Dec; 17(26):3493-8. PubMed ID: 10030673
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-33/ST2 axis promotes epithelial cell transformation and breast tumorigenesis via upregulation of COT activity.
Kim JY; Lim SC; Kim G; Yun HJ; Ahn SG; Choi HS
Oncogene; 2015 Sep; 34(38):4928-38. PubMed ID: 25531326
[TBL] [Abstract][Full Text] [Related]
11. MyD88, IRAK1 and TRAF6 knockdown in human chondrocytes inhibits interleukin-1-induced matrix metalloproteinase-13 gene expression and promoter activity by impairing MAP kinase activation.
Ahmad R; Sylvester J; Zafarullah M
Cell Signal; 2007 Dec; 19(12):2549-57. PubMed ID: 17905570
[TBL] [Abstract][Full Text] [Related]
12. c-Jun activation is required for 4-hydroxytamoxifen-induced cell death in breast cancer cells.
Madeo A; Vinciguerra M; Lappano R; Galgani M; Gasperi-Campani A; Maggiolini M; Musti AM
Oncogene; 2010 Feb; 29(7):978-91. PubMed ID: 19935718
[TBL] [Abstract][Full Text] [Related]
13. Honokiol thwarts gastric tumor growth and peritoneal dissemination by inhibiting Tpl2 in an orthotopic model.
Pan HC; Lai DW; Lan KH; Shen CC; Wu SM; Chiu CS; Wang KB; Sheu ML
Carcinogenesis; 2013 Nov; 34(11):2568-79. PubMed ID: 23828905
[TBL] [Abstract][Full Text] [Related]
14. A peptide fragment of ependymin neurotrophic factor uses protein kinase C and the mitogen-activated protein kinase pathway to activate c-Jun N-terminal kinase and a functional AP-1 containing c-Jun and c-Fos proteins in mouse NB2a cells.
Adams DS; Hasson B; Boyer-Boiteau A; El-Khishin A; Shashoua VE
J Neurosci Res; 2003 May; 72(3):405-16. PubMed ID: 12692907
[TBL] [Abstract][Full Text] [Related]
15. Menin uncouples Elk-1, JunD and c-Jun phosphorylation from MAP kinase activation.
Gallo A; Cuozzo C; Esposito I; Maggiolini M; Bonofiglio D; Vivacqua A; Garramone M; Weiss C; Bohmann D; Musti AM
Oncogene; 2002 Sep; 21(42):6434-45. PubMed ID: 12226747
[TBL] [Abstract][Full Text] [Related]
16. Peptidoglycan induces interleukin-6 expression through the TLR2 receptor, JNK, c-Jun, and AP-1 pathways in microglia.
Lin HY; Tang CH; Chen JH; Chuang JY; Huang SM; Tan TW; Lai CH; Lu DY
J Cell Physiol; 2011 Jun; 226(6):1573-82. PubMed ID: 20945380
[TBL] [Abstract][Full Text] [Related]
17. MLK3 is critical for breast cancer cell migration and promotes a malignant phenotype in mammary epithelial cells.
Chen J; Miller EM; Gallo KA
Oncogene; 2010 Aug; 29(31):4399-411. PubMed ID: 20514022
[TBL] [Abstract][Full Text] [Related]
18. IL-17A and IL-17F stimulate chemokines via MAPK pathways (ERK1/2 and p38 but not JNK) in mouse cultured mesangial cells: synergy with TNF-alpha and IL-1beta.
Iyoda M; Shibata T; Kawaguchi M; Hizawa N; Yamaoka T; Kokubu F; Akizawa T
Am J Physiol Renal Physiol; 2010 Mar; 298(3):F779-87. PubMed ID: 20042461
[TBL] [Abstract][Full Text] [Related]
19. Mutant human tumor suppressor p53 modulates the activation of mitogen-activated protein kinase and nuclear factor-kappaB, but not c-Jun N-terminal kinase and activated protein-1.
Gulati AP; Yang YM; Harter D; Mukhopadhyay A; Aggarwal BB; Benzil DL; Whysner J; Albino AP; Murali R; Jhanwar-Uniyal M
Mol Carcinog; 2006 Jan; 45(1):26-37. PubMed ID: 16267831
[TBL] [Abstract][Full Text] [Related]
20. Hyul-Tong-Ryung suppresses PMA-induced MMP-9 expression by inhibiting AP-1-mediated gene expression via ERK 1/2 signaling pathway in MCF-7 human breast cancer cells.
Kim KS; Yao L; Lee YC; Chung E; Kim KM; Kwak YJ; Kim SJ; Cui Z; Lee JH
Immunopharmacol Immunotoxicol; 2010 Dec; 32(4):600-6. PubMed ID: 20131957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
